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Hematopoietic progenitor cells (HPCs) from granulocyte colony-stimulating factor (G-CSF)emobilized pe-
ripheral blood (G-PB), bone marrow (BM), or umbilical cord blood (CB) have differing biological properties
and differing kinetics of engraftment post-transplantation, which might be explained, at least in part, by
differing gene and miRNA expression patterns. To assess the differences in gene and miRNA expression, we
analyzed whole genome expression proﬁles as well as the expression of 384 miRNAs in CD34þ cells isolated
from 18 healthy individuals (6 individuals per subtype of HPC source). We identiﬁed 43 genes and 36 miRNAs
differentially expressed in the various CD34þ cell sources. We observed that CD34þ cells from CB and BM
showed similar gene and miRNA expression proﬁles, whereas CD34þ cells from G-PB had a very different
expression pattern. Remarkably, 20 of the differentially expressed genes are targets of the differentially
expressed miRNAs. Of note, the majority of genes differentially expressed in CD34þ cells from G-PB are
involved in cell cycle regulation, promoting the process of proliferation, survival, hematopoiesis, and cell
signaling, and are targets of overexpressed and underexpressed miRNAs in CD34þ cells from the same source.
These data suggest signiﬁcant differences in gene and miRNA expression among the various HPC sources used
in transplantation. We hypothesize that the differentially expressed genes and miRNAs involved in cell cycle
and proliferation might explain the differing kinetics of engraftment observed after transplantation of he-
matopoietic stem cells obtained from these different sources.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION of chemokine signaling, mainly through the SDF-1/CXCR4
Various sources of hematopoietic progenitor cells (HPCs)
are available for hematopoietic stem cell transplantation
(HSCT), including bone marrow (BM), umbilical cord blood
(CB), and peripheral blood (PB), in some casesmobilizedwith
granulocyte colony-stimulating factor (G-CSF) (G-PB) [1-3].
The absolute number and intrinsic biological properties of
HPCs differ among these 3 sources, affecting the speed of
hematopoietic recovery after HSCT. It has been demonstrated
in the clinical setting that HPCs from G-PB provide more
rapid recovery of neutrophils and platelets after HSCT [4,5]
compared with HPCs from BM or CB [6].
Although the majority of HPCs in BM are in a dormant
state during homeostasis, these cells are rapidly and efﬁ-
ciently activated after exposure to G-CSF [7]. Thus, G-CSF
administration could account for the distinct phenotypic
and biological features of mobilized HPCs compared with
HPCs residing in the BM. Thus, HPCs enter the cell cycle after
G-CSF exposure [8]. In addition, G-CSF induces a down-
regulation of cell adhesion molecules and desensitizationedgments on page 638.
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14.01.022axis, favoring HPC mobilization to PB [9,10]. The impact of
G-CSF on the biological properties of HPCs either by a direct
effect or by causing their detachment from the hemopoietic
niche is presently unknown.
MicroRNAs (miRNAs) are small, noncoding RNA mole-
cules, 19-22 nucleotides in size, that regulate gene expres-
sion at the posttranscriptional level. miRNAs are involved
in numerous biological processes, including development,
differentiation, proliferation, and cell death [11]. Several
studies have reported that miRNAs and gene expression
differ among the different hematopoietic cell lineages during
development [12-14]; however, there is little information on
the differences in miRNA and gene expression proﬁles
among these lineages used in HSCT.
Given this background, we hypothesized that the bio-
logical differences described in HPCs obtained from BM, CB,
and G-PB might be related to a unique gene and/or miRNA
expression proﬁle within each subset, and that these varying
patterns in gene and miRNA expression might explain, at
least in part, the clinical differences observed after HSCTwith
HPCs from these different sources.
MATERIALS AND METHODS
Samples
CD34þ progenitor cells were collected from 6 healthy donors for each
type of HPC source: CB, BM, and PB both before and on the ﬁfth day afterTransplantation.
Figure 1. miRNA expression by HPC source. Unsupervised hierarchical cluster analysis performed with the miRNAs differentially expressed in HPCs from G-PB, BM,
and CB. Each numbered column represents an individual sample, and each row represents a single miRNA. Red and green indicate miRNA expression levels in
logarithmic scale. Statistical analysis was performed using the nonparametric Kruskal-Wallis test.
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CB samples were obtained from umbilical cord units not used for HSCT from
the Gynecology and Obstetrics Department of the University Hospital Virgen
del Rocío, Seville. Samples from BM, PB, and G-PB were collected from do-
nors included in the allogeneic HSCT program at the hospital’s Hematology
Department.
The hospital’s Ethics Committee provided Institutional Review Board
approval for this study, and informed consent was obtained from all donors
in accordance with the Declaration of Helsinki.Isolation of HPCs
Mononuclear cells were collected from all samples by density-gradient
centrifugation with Ficoll-Paque solution (Amersham Biosciences, Uppsala,
Sweden). The CD34þ cells were isolated in an AutoMACS Pro Separator
(Miltenyi Biotec, Bergisch Gladbach, Germany) by positive immunomagnetic
selection using the CD34 MACS microbead Human Kit (Miltenyi Biotec).
Further, for higher-purity isolation, CD34þ cells were sorted by ﬂow
cytometry (MoFlo, Beckman Coulter, Brea, CA). For this purpose, cells were
incubated with the monoclonal antibodies CD34-PE and CD45-FITC (BD
Table 1
miRNA Expression Levels
miRNA Relative Expression (Log Ratio) P Value
G-PB CB BM
hsa-miR-517c 3.31 2.59 6.00 .002
hsa-miR-130a 2.28 7.59 10.92 .004
hsa-let-7g 0.91 4.13 1.07 .004
hsa-miR-222 0.75 9.34 7.79 .002
hsa-miR-142-3p 0.64 9.95 11.09 .006
hsa-miR-125a-3p 0.58 4.38 7.72 .007
hsa-miR-93 0.54 1.85 2.14 .007
hsa-miR-10a 0.22 8.39 7.70 .003
hsa-miR-92a 0.18 14.00 13.45 .002
hsa-miR-125a-5p 0.04 5.55 6.16 .003
hsa-miR-129-3p 0.10 1.15 7.03 .003
hsa-miR-519d 0.10 5.87 3.02 .003
hsa-miR-105 0.10 6.25 7.64 .002
hsa-miR-133b 0.10 6.43 6.11 .004
hsa-miR-127-5p 0.10 7.73 4.63 .002
hsa-miR-10b 0.10 8.12 9.01 .003
hsa-miR-9 0.10 9.65 11.07 .002
hsa-miR-22 0.10 16.75 17.46 .003
hsa-miR-106b 0.11 5.21 7.00 .001
hsa-miR-20a 0.13 2.20 0.05 .008
hsa-miR-532-5p 0.20 3.67 1.25 .008
hsa-miR-221 0.21 7.41 10.75 .002
hsa-miR-106a 0.30 15.68 19.02 .002
hsa-miR-323 0.35 12.85 12.96 .003
hsa-miR-126 0.62 7.52 5.71 .001
hsa-miR-142-5p 0.69 4.43 5.90 .003
hsa-miR-411 0.77 5.11 2.43 .001
hsa-miR-335 1.10 2.95 0.98 .006
hsa-miR-140-5p 1.23 3.70 1.39 .005
hsa-miR-141 1.35 9.18 10.28 .002
hsa-miR-107 1.38 9.08 10.72 .001
hsa-miR-27a 1.56 1.14 0.29 .009
hsa-miR-320 1.56 11.11 9.50 .002
hsa-miR-103 1.73 3.86 2.00 .003
hsa-miR-143 2.23 5.83 7.28 .002
hsa-miR-128 3.95 0.32 3.02 .007
Statistical signiﬁcance: P < .01.
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ature. Populations were selected based on the intensity of antibodies, as well
as forward-scatter and side-scatter components. Dead cells were discarded
before separation. The purity of the isolated CD34þ cells exceeded 95% in all
cases.
RNA Extraction
Total RNA was extracted by TRIsure (Bioline, Luckenwalde, Germany) in
all samples. RNA quality and integrity were veriﬁed with the Bioanalyzer
2100 system (Agilent Technologies, Santa Clara, CA). A RNA integrity number
>7.5 was required for further analyses of gene expression proﬁling.
miRNA Expression
The expression proﬁles of 384 miRNAs were analyzed in samples of
CD34þ cells from CB, BM, and PB/G-PB. Total RNA (150 ng) was reverse-
transcribed using the miRNA TaqMan Reverse-Transcription Kit (Applied
Biosystems, Foster City, CA). cDNA was loaded on to the TaqMan Human
MicroRNA v2.0 Arrays (Applied Biosystems), which were subsequently
analyzed on a 7900 HT Fast Real Time PCR System (Applied Biosystems). SDS
2.3 and RQManager 1.2 software (both from Applied Biosystems) were used
for the array analyses. Undetectable miRNAs were excluded for further an-
alyses. Data were normalized using the average of the endogenous small-
nucleolar RNU48 and the noncoding small nuclear U6, both included in
the array. The CD34þ cell samples from PB served as the control group.
miRNA expression levels were obtained by the 2DDCT method.
Gene Expression
We analyzed the whole genome expression proﬁle in the same samples
using the Whole Human Genome Oligo Microarray Kit 4  44K (Agilent
Technologies). Total RNA (200 ng) was reverse-transcribed to cRNA and
labeled with the two-color Low Input Quick Amp Labeling Kit (Agilent
Technologies). cRNA quality and integrity were veriﬁed with the Bioanalyzer
2100 System (Agilent Technologies). Each analyzed sample was labeled with
cyanine 5 and hybridized against a pool of cyanine 3elabeled RNA of CD34þ
cells from PB as the reference group. The microarrays were scanned in a
GenePix Reader (Molecular Devices, Sunnyvale, CA).
Validation of Signiﬁcant Genes
The expression of signiﬁcant genes was validated by quantitative real-
time polymerase chain reaction (qRT-PCR) using Quantitec Primer Assays
and the Quantitec SYBR green Kit (both from Qiagen, Hilden, Germany) in a
7900 HT Fast Real Time PCR System (Applied Biosystems). Data were
normalized to the housekeeping gene b-ACTIN, and the same group of
samples of CD34þ cells from PB used for the hybridization experiments
served as a control. The relative gene expression levelswere calculated using
the 2DDCT method.
Engraftment Data
Data on platelet and neutrophil recovery after HSCT with G-PB and BM
were obtained from the recipients’ clinical ﬂow charts. Data on engraftment
after HSCT with CB were obtained from a series of 6 patients undergoing CB
transplantation at our institution in the same time period as those under-
going G-PB and BM transplantations. None of the CB samples analyzed for
gene and miRNA expression in the present study was used for clinical
purposes. Day of platelet engraftment was deﬁned as the ﬁrst day with a
stable count >20  10e9/L without transfusion and neutrophil engraftment
was deﬁned as the ﬁrst day with a stable count >0.5  10e9/L.
Statistical Analysis
Unsupervised hierarchical clustering of miRNA and gene expression
data were performed using average linkage and Euclidean distance. miRNAs
and genes differentially expressed among the different HPC sources were
identiﬁed using the nonparametric Kruskal-Wallis test. To obtain positive
and negative expression values, data were transformed to logarithmic scale.
All analyses were performed using MultiExperimentViewer 4.7.1. Functions
of the miRNAs and genes of interest were determined from various
online databases (http://www.targetscan.org, http://www.mirbase.org, http://
www.geneontology.org, and http://www.ingenuity.com).
Intragroup differences in gene expression determined by qRT-PCR and
in kinetics of engraftment based on clinical parameters were assessed by
ANOVA with Bonferroni post hoc adjustment.
Western Blot Analysis
For protein preparation, CD34þ cells from G-PB, BM, and CB were ho-
mogenized in ice-cold 20 mM Tris buffer (pH 7.3), containing 2 mM
Dithiothreitol, 1% Amidosulfobetaine, 1% nonyl phenoxypolyethoxylethanol,
150 mM NaCl, 1 mM Na3VO4, 10 mM NaF (Sigma Aldrich, St. Louis, MO) and10% protease inhibitor cocktail (Roche, Mannheim, Germany). Homogenized
samples were incubated at 4C for 30 minutes and then centrifuged at high
speed in a microcentrifuge, after which protein-containing supernatant was
collected. Protein concentration was determined using the Pierce BCA Pro-
tein Assay KiteReducing Agent Compatible (Thermo Scientiﬁc, Rockford, IL).
From each sample, 15 mg of protein was separated by electrophoresis on
sodium dodecyl sulfateepolyacrylamide gels and electroblotted onto poly-
vinylidene ﬂuoride membranes. Blots were incubated in TTBS blocking so-
lution (2% BSA in Tris-buffered saline and 0.1% Tween-20), followed by
overnight cold incubation with the following antibodies: anti-HSPA1A
(ab5439; Abcam, Cambridge, UK), anti-CRLF3 (ab103540; Abcam) and
antieb-actin (ab6276; Abcam). The membranes were then washed with
TTBS and incubated with either a horseradish peroxidase (HRP)-conjugated
donkey anti-rabbit IgG antibody (711-035-152; Jackson ImmunoResearch,
Baltimore, MD) or HRP-conjugated donkey anti-mouse IgG antibody (715-
035-150; Jackson ImmunoResearch). Antibody detection was performed
with an enhanced chemiluminescence reaction (Western Blot Luminol Re-
agent; sc-2048; Santa Cruz Biotechnology, Dallas, TX).RESULTS
miRNA Expression in HPCs from BM, CB, and G-PB
miRNA expression proﬁles were determined in CD34þ
cells from PB, G-PB, BM, and CB. Out of 384 miRNAs, 72 were
undetectable across all samples and were excluded from
further analysis. We performed unsupervised hierarchical
clustering comparing the miRNA expression of HPCs from
BM, CB, and G-PB with respect to the PB samples. The ob-
tained cluster identiﬁed 2 groups, 1 group comprising the G-
PB samples and the other group comprising the BM and CB
samples, suggesting that HPCs from BM and CB have similar
Table 2
Gene Expression Levels
Gene Relative Expression (Log Ratio) P Value
G-PB CB BM
MPO 2.44 1.31 0.24 .009
BIRC5 1.31 0.52 1.29 .003
IGLL1 1.31 1.21 0.80 .008
KIAA0101 1.10 0.30 1.13 .006
ZWINT 0.89 0.47 1.25 .005
PHIP 0.66 0.44 0.90 .005
TYMS 0.61 0.59 1.52 .004
TUBB2A 0.53 0.09 0.42 .003
ZFP91 0.48 1.05 0.87 .007
SVOPL 0.39 1.16 0.43 .009
PDE4B 0.36 1.64 1.09 .007
ABCB9 0.32 2.63 1.07 .007
GHDC 0.06 0.66 0.27 .006
ZNF776 0.13 0.92 0.63 .009
IDS 0.38 0.63 1.24 .004
DPYSL3 0.68 0.25 0.55 .007
NR1H3 0.69 0.60 0.96 .007
GABRA1 0.70 0.69 0.09 .008
HSP90AA2 0.77 0.41 0.17 .005
AHNAK 0.82 0.25 1.68 .001
CIRBP 0.82 0.02 1.12 .003
TPM2 0.86 0.13 0.67 .006
HIST2H2BE 0.92 0.52 0.77 .003
LMNA 0.93 0.92 0.60 .003
HOXA9 0.94 0.01 0.87 .007
SIPA1L1 1.05 0.53 0.51 .003
CCR3 1.11 0.67 0.64 .008
NKG7 1.15 1.29 0.45 .008
NEAT1 1.17 0.71 0.49 .006
TMX3 1.18 0.92 0.10 .006
ACAA1 1.19 1.17 0.97 .003
CRLF3 1.19 1.37 0.22 .004
ZBTB20 1.31 0.44 0.39 .008
NACAD 1.35 0.66 0.49 .003
COL12A1 1.38 0.06 1.45 .002
NKX2-1 1.43 0.13 0.93 .003
VNN2 1.89 0.33 0.40 .004
HIST2H2AA3 1.97 0.74 0.18 .003
ATP10D 2.13 0.46 0.43 .009
HIST1H2AC 2.58 0.58 0.63 .006
MIAT 2.65 0.18 0.22 .003
VMP1 2.74 0.90 0.28 .003
HSPA1A 4.30 0.12 1.18 .002
Statistical signiﬁcance: P < .01.
Figure 2. Gene expression by HPC source. Unsupervised hierarchical cluster
analysis performed with the genes differentially expressed in HPCs from G-PB,
BM, and CB. Each numbered column represents an individual sample, and each
row represents a single gene. Red and green indicate gene expression levels in
logarithmic scale. Statistical analysis was performed using the nonparametric
Kruskal-Wallis test.
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in HPCs from G-PB.
miRNAs differentially expressed in the different HPC
sources were identiﬁed using the nonparametric Kruskal-
Wallis test. All miRNAs with a P value <.01 were consid-
ered signiﬁcant. Figure 1 shows unsupervised hierarchical
clusters including only the differentially expressed miRNAs.
We identiﬁed 36 miRNAs with expression levels varying
among the different sources. Among these, 25 miRNAs were
overexpressed and 9 were underexpressed in HPCs from G-
PB, whereas 18 miRNAs were overexpressed and 18 were
underexpressed in HPCs from BM and CB. Moreover, HPCs
from BM and CB displayed no signiﬁcant differences in the
expression pattern for 30 miRNAs (Table 1).
Among the miRNAs differentially expressed in HPCs from
G-PB, miR103, miR106a, miR125a-5p, miR126, miR140-5p,
miR20a, miR221, and miR320 were overexpressed, whereas
these miRNAs appeared underexpressed in both BM and CB.
In contrast, miR93 was underexpressed in HPCs from G-PB
and overexpressed in the other 2 HPC sources. All of these
Figure 3. Validation of signiﬁcant genes. Expression levels of genes differentially expressed in HPCs from G-PB, BM, and CB relative to HPCs from PB as determined by
qRT-PCR. Statistical analysis was performed with ANOVA. *P < .01.
A. Báez et al. / Biol Blood Marrow Transplant 20 (2014) 630e639634miRNAs are involved in control of the cell cycle, apoptosis,
cell proliferation, differentiation, and immune response.
Gene Expression in HPCs from BM, CB, and G-PB
We performed high-throughput gene expression analysis
of the same samples by microarray technology. Unsuper-
vised hierarchical clustering comparing samples from G-PB,
BM, and CB with PB samples identiﬁed 2 clusters, 1 including
G-PB samples and the other comprising BM and CB samples.
This ﬁnding suggests that HPCs from BM and CB have similar
gene expression proﬁles, whereas HPCs from G-PB have a
different expression pattern.
Genes differentially expressed among the different HPC
sources were identiﬁed using the nonparametric Kruskal-
Wallis test. Differences in expression with P < .01 were
considered signiﬁcant. We identiﬁed 43 genes differentially
expressed among the 3 sources (Figure 2). In HPCs obtainedfrom G-PB, 30 genes were up-regulated and 13 were down-
regulated; in HPCs from CB, 25 genes were up-regulated
and 18 were down-regulated; and in HPCs from BM, 18
genes were up-regulated and 25 were down-regulated
(Table 2). Moreover, in HPCs from BM and CB, 28 genes
exhibited the same expression pattern.
Among the genes differentially expressed in G-PB were
down-regulated genes GHDC, IGLL1, KIAA0101, PDE4B, PHIP,
SVOPL, TUBB2A, TYMS, ZFP91, and ZWINT and up-regulated
genes AHNAK, DPYSL3, GABRA1, HIST2H2BE, HOXA9, HSPA1A,
IDS, LMNA,NACAD,NEAT1,NKX2-1,NR1H3, TPM2, and ZBTB20.
Most of these genes are involved in regulation of the cell
cycle, cell growth and proliferation, cell death and survival,
cell differentiation, and immune response.
Finally, to validate the high-throughput screening, we
conﬁrmed the expression of 6 genes (CRLF3, ZWINT, HSPA1A,
VMP1, VNN2, and TMX3) out of the 43 differentially expressed
A. Báez et al. / Biol Blood Marrow Transplant 20 (2014) 630e639 635genes by qRT-PCR. A group of CD34þ cell samples from PB
served as a control. These genes were selected because each
is representative of the different biological processes found
in this study and because, according to online databases
(http://www.targetscan.org and http://www.mirbase.org),
all are targets of the differentially expressed miRNAs iden-
tiﬁed in this study. Our results verify that HPCs from G-PB
had a different gene expression proﬁle compared with HPCs
from BM and CB. Expression of the genes up-regulated in
HPCs from G-PB (CRLF3, HSPA1A, VMP1, VNN2, and TMX3)
was higher compared with that of genes up-regulated in
HPCs from BM and CB. In addition, a gene down-regulated in
HCPs from G-PB (ZWINT) appeared to be up-regulated in
HPCs from BM and CB (Figure 3).
miRNA and Gene Expression Pattern in HPCs from G-PB
We further analyzed the differences between HPCs from
G-PB and HPCs from BM and CB through paired unsuper-
vised analysis. We compared gene and miRNA expression
proﬁles in CD34þ cells from PB versus CB, BM, and G-PB
using the nonparametric Mann-Whitney test. The differ-
ences in gene and miRNA expression with P < .01 were
considered signiﬁcant. Regarding gene expression proﬁles,
we found no signiﬁcant differences between HPCs from PB
and HSCs from G-PB, BM, or CB (Figure 4A-C); however, we
found more similarities in miRNA expression pattern of
HPCs between PB and G-PB than between PB and BM or
between PB and CB (Figure 5A-C). These results suggest thatFigure 4. Gene expression pattern by HPC source versus PB. Unsupervised hierarchica
versus PB (A), CB versus PB (B), and BM versus PB (C). Each numbered column represe
indicate gene expression levels in logarithmic scale. Statistical analysis was performethe differences in miRNA expression pattern of HPCs from G-
PB compared with HPCs from BM and CB might not be
attributable to a direct effect of G-CSF on HPCs, but rather
could be related to G-CSF’s effect on the detachment of HPCs
from the hematopoietic niche.
Protein Synthesis in HPCs from BM, CB, and G-PB
We analyzed the expression of some proteins to verify the
results observed in gene expression data by microarray
technology and qRT-PCR. We performed Western blot ana-
lyses comparing the expression of CRLF3 and HSPA1A pro-
teins in HPCs from G-PB, BM, and CB with respect to
expression of b-actin. We chose these 2 proteins because
their encoding genes were overexpressed in HPCs from G-PB
compared with HPCs from the other 2 sources. Remarkably,
both proteins had higher expression levels in HPCs from G-
PB than in HPCs from BM or CB (Figure 6A). These protein
analyses were performed in replicate; expression levels are
shown in Figure 6B and C.
Engraftment
To correlate the data for gene, miRNA and protein
expression with the kinetics of engraftment, we evaluated
the recovery of neutrophils and platelets in patients who
underwent HSCT using the HPCs from BM and G-PB used in
the gene and miRNA expression molecular analyses, as well
as HPCs from CB (Table 3). In the case of CB, the clinical pa-
rameters were obtained from patients who underwent HSCTl cluster analysis was performed with the genes differentially expressed in G-PB
nts an individual sample, and each row represents a single gene. Red and green
d using the nonparametric Mann-Whitney test.
Figure 5. miRNA expression pattern in HPC sources versus PB. Unsupervised hierarchical cluster analysis was performed with the miRNAs differentially expressed in
G-PB versus PB (A), CB versus PB (B), and BM versus PB (C). Each numbered column represents an individual sample, and each row represents a single miRNA. Red and
green indicate gene expression levels in logarithmic scale. Statistical analysis was performed using the nonparametric Mann-Whitney test.
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periments, because in this group of samples, the entire um-
bilical cord was used for RNA and protein preparation. As
expected, patients who received HPCs from G-PB had
signiﬁcantly shorter median times to neutrophil and platelet
recovery signiﬁcantly shorter compared with patients who
received HPCs from BM and CB (Table 4).
DISCUSSION
Previous studies have examined the biological properties
of HPCs obtained from the 3 sources currently available fortransplantation: BM, CB and G-PB [15,16]. Those studies
focused on cloning efﬁciency, proliferation and response to
cytokine stimulation, progeny, and recovery after HSCT, and
reported a faster rate of recovery with the use of HPCs from
G-PB; however, their data do not fully explain the different
engraftment outcomes in the recipients of transplants of
HPCs from these different sources.
Although gene and miRNA expression proﬁles have been
studied in hematologic cell lineages and in HPCs [17-21], the
relationship between gene and miRNA expression and the
properties of the HPCs obtained from the currently available
Figure 6. Protein expression by HPC source. (A) Western blot analysis of
HSPA1A and CRLF3 proteins comparing HPCs from G-PB, BM, and CB. (B and C)
Protein levels of HSPA1A (B) and CRLF3 (C) in HPCs from G-PB, BM, and CB
normalized with respect to b-actin (n ¼ 2).
Table 4
Engraftment Data
HPC Source Time to Recovery after HSCT, d
Neutrophils >500 Platelets >20,000 Platelets >50,000
G-PB 16.0  0.84 11.8  0.37 14.8  0.86
BM 18.67  2.28 17.0  1.70 31.75  4.15
CB 21.3  2.5 29.7  2.67* 39.5  2.5
Median time of neutrophil and platelet recovery in 6 patients after HSCT.
Statistical analysis performed with ANOVA.
* P < .01, CB versus G-PB or BM.
Table 5
Target Genes
Target gene Source miRNAs
CRLF3 G-PB, BM, and CB miR10a, miR92a
HSP90AA2 G-PB, BM, and CB miR130a
VMP1 G-PB, BM, and CB miR103a, miR92a
VNN2 G-PB, BM, and CB miR10a, miR125a-3p
KIAA0101 BM and CB miR103, miR106a, miR20a, miR320
PHIP BM and CB miR103, miR126, miR320
ZWINT BM and CB miR106a, miR320
PDE4B BM and CB miR103, miR106a, miR20a, miR320
ZFP91 BM and CB miR103, miR106a, miR126,
miR140-5p, miR20a,
miR221, miR320
A. Báez et al. / Biol Blood Marrow Transplant 20 (2014) 630e639 637sources remains largely unknown. In this regard, we hy-
pothesized that different patterns of gene and miRNA
expression of HPCs in the G-PB, BM, and CB might have
clinical implications and could explain, at least in part, the
differing kinetics of engraftment observed after HSCT with
these 3 types of HPCs.
We found that gene and miRNA expression proﬁles of
HPCs differ depending on their source: G-PB, BM, or CB. We
observed that the gene and miRNA expression patterns of
HPCs are similar in BM and CB, whereas HPCs fromG-PB have
a unique expression proﬁle. Of note, most of the differentially
expressed genes and miRNAs are involved in the cell cycle
and proliferation, which might explain the differing kinetics
of engraftment observed after transplantation of HPCs from
the 3 different sources.
We ﬁrst identiﬁed 36 miRNAs differentially expressed in
the 3 sources of HPCs, most of which appeared to be over-
expressed in HPCs from G-PB. Among these, 8 miRNAs were
overexpressed only in HPCs from G-PB (miR103, miR106a,
miR125a-5p, miR126, miR140-5p, miR20a, miR221, and
miR320). Of note, these 8 miRNAs are involved in control of
the cell cycle, decreasing apoptosis and promoting cell pro-
liferation and differentiation [22-25]. In contrast, in HPCs
from BM and CB, the same number of miRNAs were over-
expressed and underexpressed, with similar expression
patterns in both.Table 3
Graft Characteristics
HPC Source Graft Characteristics
CD3þ T cells ( 106/kg) CD34þ cells ( 106/kg)
G-PB 245.3  7.71 6.2  0.57
BM 33.27  3.37 3.48  0.52
CB 13  1.48 0.2  0.06
Statistical analysis performed using ANOVA; P < .01 in all comparisons
between groups.We then identiﬁed 43 genes differentially expressed
among the 3 sources of HPCs and again we found more dif-
ferences in HPCs fromG-PB comparedwith HPS from BM and
CB. We identiﬁed 10 down-regulated genes (GHDC, IGLL1,
KIAA0101, PDE4B, PHIP, SVOPL, TUBB2A, TYMS, ZFP91, and
ZWINT) and 14 up-regulated genes (AHNAK, DPYSL3, GABRA1,
HIST2H2BE, HOXA9, HSPA1A, IDS, LMNA, NACAD, NEAT1,
NKX2-1, NR1H3, TPM2, and ZBTB20) only in HPCs from G-PB.
The majority of these genes are related to the cell cycle,
promoting cell proliferation, hematopoiesis, and the inmune
response. Remarkably, 20 of these 43 differentially expressed
genes are targets of the 36 miRNAs also differentially
expressed in this study, based on information in the afore-
mentioned databases (Table 5).
Interestingly, the direction of the change in the expres-
sion of these target genes was opposite of that in the
expression of miRNAs. Five of these target genes were up-
regulated only in HPCs from G-PB. AHNAK and HIST2H2BE
are known to promote cell proliferation [26,27], whereas IDS
participates in cellular secretion [28]. HSPA1A and GABRA1
have important roles in inhibiting the apoptotic process
when up-regulated [29,30]. In contrast, 8 target genes
appeared to be down-regulated in HPCs fromG-PB compared
with HPCs from BM and CB. The down-regulation of KIAA010,
ZWINT, PDE4B, ZFP91, TYMS, and IGLL1 could affect the cell
cycle, cell proliferation, apoptosis, cell signaling and hema-
topoiesis [31-36], and the low expression of PHIP and GHDC
could lead to defects in gene expression and the transcription
process [37].GHDC BM and CB miR103, miR221
TYMS BM and CB miR140-5p, miR20a
IGLL1 BM and CB miR106a y miR221
TMX3 G-PB and CB miR106a
IDS G-PB miR93
AHNAK G-PB miR93
BIRC5 BM miR519d
ABCB9 CB miR27a
HSPA1A G-PB miR93
HIST2H2BE G-PB miR93
GABRA1 G-PB miR93
Listed are differentially expressed genes among the different HPC sources
regulated by the differentially expressed miRNAs.
A. Báez et al. / Biol Blood Marrow Transplant 20 (2014) 630e639638Overall, our data suggest that the genes expressed in HPCs
from G-PB are involved in the cell cycle, promoting cell dif-
ferentiation and proliferation. This may help explain the
faster engraftment of G-PB HPCs after HSCT compared with
HPCs from BM and CB.
Validation of some of these target genes (CRLF3, ZWINT,
HSPA1A, VMP1, VNN2 TMX3) by qRT-PCR indicates that HPCs
from BM and CB have a similar gene expression pattern with
respect to HPCs fromG-PB. Most of the genes up-regulated in
HPCs from G-PB had lower expression levels in HPCs from
BM and CB. In addition, 1 gene, ZWINT, that was down-
regulated after mobilization appeared to be up-regulated in
HPCs from BM and CB compared with HPCs from PB. More-
over, analysis of expression levels of the proteins encoded by
2 of these validated genes (HSPA1A and CRLF3) conﬁrmed a
different expression pattern in HPCs from G-PB compared
with that in HPCs from BM and CB, as observed in gene and
miRNA studies.
In addition, to examine the differences between HPCs
fromG-PB and HPCs from BM and CB, we compared gene and
miRNA expression proﬁles of HPCs from PB and HPCs from all
3 sources. We found no statistically signiﬁcant differences in
gene expression proﬁle between HPCs from PB and HPCs
from the G-PB, BM, or CB; however, the miRNA expression
proﬁle of HPCs from PB was closer to that of HPCs from G-PB
than to that of HPCs from BM or from CB. This ﬁnding may
suggest that the detachment of HPCs from BM stroma
induced by G-CSF can alter their miRNA expression proﬁle,
up-regulating or down-regulating miRNAs not expressed in
this manner in BM and CB.
Finally, to correlate gene, miRNA, and protein expression
data and clinical outcomes, we compared the kinetic of
engraftment among patients undergoing HSCT with HPCs
from G-PB, BM, or CB. As expected, neutrophil and platelet
recovery was faster in the patients receiving G-PB HPCs.
Although most of the difference in recovery has been
attributed to the differing amounts of HPCs infused from
each source, our data also suggest that these varying out-
comes are a question not just of quantity but also of quality;
that is, HPCs from different sources have differing biological
properties, as demonstrated by the individual gene expres-
sion patterns.
In summary, we have demonstrated signiﬁcant differ-
ences in gene and miRNA expression proﬁles in HSCs from
the different sources currently used in HSCT. The expression
proﬁle of HPCs from G-PB differs from that of HPCs from BM
and fromCB, which seem to have similar expression patterns.
Future studies of speciﬁc genes and miRNA from the data
generated in this study may provide insight into the bio-
logical processes that contribute to posttransplantation
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